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Progressive myoclonic epilepsy (PME) is a group of disorders in
which myoclonus is a major component. Patients with PME
typically have generalized tonic–clonic or clonic seizures, mental
retardation culminating in dementia, and a neurologic syndrome
that almost always includes cerebellar dysfunction. It comprises a
heterogeneous group of inherited disorders.1,2 Conditions inwhich
PME is seen include Unverricht–Lundborg disease, sialidosis,
Gaucher’s disease, mitochondrial encephalomyelopathy with
ragged-red ﬁbers (MERRF), Lafora’s disease, neuronal ceroid
lipofuscinosis, and Dentato-Rubro-Pallido Luysian Atrophy
(DRPLA). The intensity of the various clinical features varies
depending on the etiology. Although valproate, benzodiazepines,
piracetam, zonisamide, topiramate, and levetiracetam have had a
positive impact on the control of the epilepsy, the prognosis of this
syndrome is poor.3 PME is also not responsive to open surgical
resection. Among complimentary treatment options for epilepsy
resistant tomedical and open surgical treatments, most patients so
far have been treated by vagus nerve stimulation (VNS).4,5 VNS is a
widely used neurostimulation for treatment-resistant epilepsy. Its
components are a pulse generator and a bipolar vagus nerve lead.
The generator is designed to be implanted in the patient’s chest on
the upper left side. This pulse generator produces charge-balanced
waveforms at a constant current.
The effectiveness of VNS for PME has rarely been reported.6 The
purpose of this study was to evaluate the efﬁcacy of VNS for PME.
2. Patients and methods
All the investigations and treatments were evaluated and
approved by the ethics committee at Seirei Hamamatsu General
Hospital.* Corresponding author. Tel.: +81 53 474 2222; fax: +81 53 475 7596.
E-mail address: ataka_fuji@sis.seirei.or.jp (A. Fujimoto).
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A 16-year-old, right hand-dominant man visited our hospital
with bilateral hand myoclonus, epileptic seizures, cerebellar
symptoms, and mild mental impairment. He had exhibited
myoclonus and epileptic seizures since 12 years of age. These
symptoms gradually worsened. The seizure frequency and
intensity also deteriorated and occasionally progressed to status
epilepticus. This condition was diagnosed as PME based on the
presence of EEG abnormalities, myoclonus, and mental retarda-
tion. Muscle biopsy and genetic studies showed mitochondrial
encephalomyelopathy with ragged-red ﬁbers (MERRF). He used to
be on valproate, clonazepam, and topiramate, but he developed
valproate-induced acute pancreatitis. Currently, he had been on
levetiracetam 3000 mg/day, clonazepam 1.5 mg/day, and topir-
amate 300 mg/day. The seizure frequency was weekly. Status
epilepticus occurred once to twice a year. He was basically
wheelchair bound, walking occasionally with assists. He had
intentional and resting tremor and truncal ataxia.
EEG showed diffuse 6–7 Hz theta activities. There were
frequent generalized poly-spike-waves. Photic stimulation in-
duced bilateral hand and eyelid myoclonus with generalized poly-
spike-wave activities. MRI showed an atrophic brain stem and
cerebellum.
VNS (VNS therapy system, Cyberonics, Inc., Houston, TX, USA)
was performed for this patient.
2.2. Patient 2
A 20-year-old woman was referred from a nearby hospital. She
was diagnosed as having Gaucher’s disease type III based on
genetic and other studies. Gaucher cells were found in her bone
marrow. Blood sampling showed deﬁcient glucosylceramidase
enzyme activity. Her siblingwas also diagnosed as having the same
disease. She started exhibiting myoclonus involving her hands and
generalized seizures at the age of 13 years. Her seizure frequency
and intensity had deteriorated gradually, becoming daily by 18
years of age. She also suffered from status epilepticus monthly.
Although she had cerebellar symptoms, she was able to walk by
herself with spasticity. She was on valproate 600 mg/day,
clonazepam 1.5 mg/day, and topiramate 400 mg/day. She was
also on enzyme replacement therapy and chaperone therapy.
EEG showed posterior dominant, 7–8 Hz alpha and theta
activities. There were frequent high-amplitude, generalized,vier Ltd. All rights reserved.
Table 1
Four PME patients who underwent VNS therapy.
Author Age Sex Syndrome Generalized Sz SE Myclonus Cerebellar Follow-up period
Vesper 31 M Undetermined Improved N/A Deteriorated N/A 8 years, followed by DBS
Smith 34 F ULS Improved N/A Improved Improved 1 year follow-up (f/u)
Our Case1 16 M MERRF Improved Improved Not deteriorated Not deteriorated 1 year 6 months f/u
Our Case2 20 F Gaucher III Improved Improved Deteriorated Not deteriorated 1 year 4 months f/u
Sz: seizure; DBS: Deep Brain Stimulation; ULS: Unverricht–Lundborg Syndrome;MERRF: mitochondria encephalomyelopathy with ragged-red ﬁbers; SE: Status Epilept icus.
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was suggestive of encephalopathy and generalized epilepsy. MRI
showed a diffuse atrophic brain for her age.
VNS was performed for this patient.
3. Results
Patient 1: Postoperatively, the patient did not show any
complications, including hoarseness, infection, or cardiac issues.
The VNS initial dosing 2 weeks after the VNS implant was: output
current, 0.25 mA; on time, 30 s/off time, 5 min; signal frequency,
30 Hz; and pulse width, 500 ms. The patient visited our outpatient
ofﬁce every 4–5 weeks until visit 5. The dosing increment was
0.25–1.25 mA. He became free of seizures 4 months after the VNS
implant. During 1 year and 8 months of follow-up, he has not
exhibited epileptic seizures and status epilepticus. His mental
retardation, myoclonus, and cerebellar symptoms have shown no
marked changes after the VNS; VNS improved only the epileptic
seizures (Table 1).
Patient 2: Postoperatively, the patient did not show any
complications, including hoarseness, infection, or cardiac issues.
The VNS initial dosing 2 weeks after the VNS implant was: output
current, 0.25 mA; on time, 30 s/off time, 5 min; signal frequency,
30 Hz; and pulse width, 500 ms. The patient visited our outpatient
ofﬁce every 4–5 weeks.
The dosing increment was 0.25–1.5 mA. Her seizure frequency
reduced gradually. She had status epilepticus 4 months after the
VNS implant, after which she has not showed status epilepticus.
During 1 year and 6 months of follow-up, she has been free from
epileptic seizures. Her mental retardation and cerebellar symp-
toms have shown no marked changes after VNS. She continues to
have severe hand myoclonus even after VNS. (Table 1)
4. Discussion
Current treatment for PME mostly relies on a combination of
valproate and benzodiazepines, usually clonazepam.7 Zonisamide
is considered amajor antimyoclonic agent.8 Topiramate also seems
to have a speciﬁc antimyoclonic effect.9 Levetiracetam has proven
efﬁcacy for photo-sensitive seizures.10 However, the results for
PME have been disappointing.
VNS was performed for two patients with PME. The VNS has
achieved seizure freedom and been effective for status epilepticus
in these two patients throughout more than 1 year of follow-up.
There have been two previous reports on PME treatedwith VNS.
Thus, including the present cases, there have been four patients
with PME who underwent VNS (Table 1), including one with
Unverricht–Lundborg disease (ULD), one with MERRF, one with
Gaucher’s disease Type III, and one that remains unclassiﬁed. VNS
improved generalized seizures in all four patients. Of these four
patients, two had status epilepticus. Thus, VNS is effective for
status epilepticus. Although VNS improved myoclonus and
cerebellar dysfunction only in Smith’s patient, the present patients
and Vesper’s patient did not respond to VNS with respect to
myoclonus, cerebellar symptoms, and mental retardation. SincePME is a progressive disorder, the efﬁcacy of VNS might decrease
over time. Two of the four patients showed deterioration in
myoclonus. We regard this as part of the progressive disease, and
not a result of VNS. Wille11 reported ﬁve patients with PME who
underwent subthalamic deep brain stimulation (DBS) system
implantation. DBS has been effective in myoclonus. One patient12
has been seizure-free with VNS and myoclonus reduction with
DBS. However, an increase in stimulation amplitudes provoked
worsening of epileptic activity or considerable side effects in all but
one of ﬁve patients. VNS seems to show efﬁcacy for ULS, MERFF,
and Gaucher’s disease. The effect of VNS might not differ by PME
etiology. VNS reduced generalized seizures and status epilepticus
in patients with PME. However, the efﬁcacy of VNS for myoclonus,
mental retardation, and cerebellar symptoms remains unclear.
5. Conclusion
VNS is useful for epileptic seizures and status epilepticus in
patients with PMEs. However, VNS might not control myoclonus,
cerebellar symptoms, and mental retardation in some patients.
Epileptic seizures and status epilepticus reduce PME patients’
quality of life. VNS can be a treatment option for medically
intractable epilepsy in PME patients. Further studies with a larger
number of patients and longer follow-up periods are needed.
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